Beremagene geperpavec-svdt (B-VEC) entered the market in 2023 as the first approved corrective treatment for dystrophic epidermolysis bullosa (DEB), a rare genetic disease affecting the skin and nails ...
Recessive dystrophic epidermolysis bullosa, also called RDEB, is one form of epidermolysis bullosa. Epidermolysis bullosa is a rare genetic condition that causes very fragile skin. With RDEB, even a ...
Dystrophic epidermolysis bullosa is a rare genetic blistering skin disease caused by mutations in COL7A1, which encodes type VII collagen (C7). Beremagene geperpavec (B-VEC) is a topical ...
Please provide your email address to receive an email when new articles are posted on . More than a quarter of patients with DEB experience ocular complications. A single patient showed complete ...
Credit: Krystal Biotech. Vyjuvek is a topical HSV-1 vector-based gene therapy. The Food and Drug Administration (FDA) has approved Vyjuvek ™ (beremagene geperpavec-svdt) for the treatment of wounds in ...
Krystal Biotech, Inc. announced that the European Commission has approved VYJUVEK® (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) from ...
Please provide your email address to receive an email when new articles are posted on . Coughing episodes, hematemesis, vomiting and choking are common disease manifestations. Treat with medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results